Abstract
The first case of COVID-19 was detected in Brazil on 25 February 2020. We report and contextualize epidemiological, demographic and clinical findings for COVID-19 cases during the first 3 months of the epidemic. By 31 May 2020, 514,200 COVID-19 cases, including 29,314 deaths, had been reported in 75.3% (4,196 of 5,570) of municipalities across all five administrative regions of Brazil. The R0 value for Brazil was estimated at 3.1 (95% Bayesian credible interval = 2.4–5.5), with a higher median but overlapping credible intervals compared with some other seriously affected countries. A positive association between higher per-capita income and COVID-19 diagnosis was identified. Furthermore, the severe acute respiratory infection cases with unknown aetiology were associated with lower per-capita income. Co-circulation of six respiratory viruses was detected but at very low levels. These findings provide a comprehensive description of the ongoing COVID-19 epidemic in Brazil and may help to guide subsequent measures to control virus transmission.
| Original language | English |
|---|---|
| Pages (from-to) | 856-865 |
| Number of pages | 10 |
| Journal | Nature Human Behaviour |
| Volume | 4 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2020 |
Bibliographical note
Publisher Copyright:© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Funding
We thank M. Gome, L. Bastos and L. M. Carvalho (MAVE) for useful discussions on SIVEP-Gripe, and we thank L. Matkin (Oxford) for technical support. This work was supported by a FAPESP (2018/14389-0) and Medical Research Council and CADDE partnership award (MR/S0195/1) (http://caddecentre.org/). W.M.S. is supported by the São Paulo Research Foundation, Brazil (2017/13981-0 and 2019/24251-9). N.R.F. is supported by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z). O.J.B. was funded by a Sir Henry Wellcome Fellowship funded by the Wellcome Trust (206471/Z/17/Z). V.H.N. and C.A.P. were supported by FAPESP (2018/12579-7). A.E.Z. and B.G. were supported by Oxford Martin School. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Ethical approval and case definitions. This retrospective national study was supported by the Brazilian Ministry of Health and ethical approval was provided by the national ethical review board (Comissão Nacional de Ética em Pesquisa; protocol number CAAE 30127020.0.0000.0068). A patient presenting with an acute respiratory syndrome (fever and at least one sign/symptom of respiratory illness) and: (1) a history of travel to a location with community transmission of COVID-19; or (2) contact with a confirmed or probable COVID-19 case in the 14d preceding symptom onset; or (3) absence of an alternative diagnosis that completely explained the clinical presentation6 was considered to have suspected COVID-19. Initially, a traveller was suspected to have COVID-19 only when arriving from China, although the definition of suspected cases associated with travel later included Japan, Singapore, South Korea, North Korea, Thailand, Vietnam and Cambodia (21 February 2020), then also Italy, Germany, Australia, the United Arab Emirates, the Philippines, France, Iran and Malaysia (25 February 2020), then also the United States, Canada, Switzerland, the United Kingdom and four additional countries (3 March 2020). From 9 March 2020 onwards, the Ministry of Health decided to start testing all hospitalized patients with severe respiratory symptoms, regardless of their travel history. Contact with a confirmed or probable COVID-19 case was defined as face-to-face or direct contact with someone known to have COVID-19, or direct contact in a healthcare setting. Moreover, patients reporting travel to an affected country in the preceding 14 d were considered imported cases. Cases not meeting this criterion were considered to be due to local transmission. Suspected COVID-19 cases were confirmed by laboratory testing (that is, molecular diagnostics with real-time quantitative PCR), or by clinical epidemiological criteria. In the latter case, the classification was used when laboratory testing was inconclusive or unavailable, as recommended by the Brazilian Ministry of Health guidelines dated 6 April 202048, and by the World Health Organization interim guidance dated 25 March 202049.
| Funders | Funder number |
|---|---|
| CADDE-Genomic-Network | |
| Sir Henry Wellcome Postdoctoral Fellowship | |
| Wellcome Trust Centre for Mitochondrial Research | 204311/Z/16/Z, 206471/Z/17/Z |
| Royal Society Sir Henry Dale Fellowship | 2018/12579-7 |
| Wellcome Trust | 204311, 206471 |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | 2018/14389-0, 2017/13981-0, 2019/24251-9 |
| Ministério da Saúde | CAAE 30127020.0.0000.0068 |
| UK Medical Research Council, Engineering and Physical Sciences Research Council | MR/S0195/1 |
ASJC Scopus subject areas
- Social Psychology
- Experimental and Cognitive Psychology
- Behavioral Neuroscience